Cargando…
Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury
In recent years, cell membrane drug delivery systems have received increasing attention. However, drug-loaded membrane delivery systems targeting therapy in myocardial ischemia–reperfusion injury (MIRI) have been relatively rarely studied. The purpose of this study was to explore the protective effe...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227294/ https://www.ncbi.nlm.nih.gov/pubmed/35736311 http://dx.doi.org/10.3390/membranes12060605 |
_version_ | 1784734137993658368 |
---|---|
author | Zhou, Tingting Yang, Xuechao Wang, Tianyi Xu, Mingming Huang, Zhanghao Yu, Runze Jiang, Yi Zhou, Youlang Shi, Jiahai |
author_facet | Zhou, Tingting Yang, Xuechao Wang, Tianyi Xu, Mingming Huang, Zhanghao Yu, Runze Jiang, Yi Zhou, Youlang Shi, Jiahai |
author_sort | Zhou, Tingting |
collection | PubMed |
description | In recent years, cell membrane drug delivery systems have received increasing attention. However, drug-loaded membrane delivery systems targeting therapy in myocardial ischemia–reperfusion injury (MIRI) have been relatively rarely studied. The purpose of this study was to explore the protective effect of platelet-membrane-encapsulated Carvedilol on MIRI. We extracted platelets from the blood of adult SD rats and prepared platelet membrane vesicles (PMVs). Carvedilol, a nonselective β-blocker, was encapsulated into the PMVs. In order to determine the best encapsulation rate and drug-loading rate, three different concentrations of Carvedilol in low, medium, and high amounts were fused to the PMVs in different volume ratios (drugs/PMVs at 2:1, 1:1, 1:2, and 4:1) for determining the optimum concentration and volume ratio. By comparing other delivery methods, including abdominal injection and intravenous administration, the efficacy of PMVs-encapsulated drug-targeted delivery treatment was observed. The PMVs have the ability to target ischemic-damaged myocardial tissue, and the concentration and volume ratio at the optimum encapsulation rate and the drug-loading rate are 0.5 mg and 1:1. We verified that PMVs@Carvedilol had better therapeutic effects compared to other treatment groups, and immunofluorescence observation showed a significant improvement in the apoptosis indicators and infarction area of myocardial cells. Targeted administration of PMVs@Carvedilol may be a promising treatment for myocardial reperfusion injury, as it significantly improves postinjury cardiac function and increases drug utilization compared to other delivery methods. |
format | Online Article Text |
id | pubmed-9227294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92272942022-06-25 Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury Zhou, Tingting Yang, Xuechao Wang, Tianyi Xu, Mingming Huang, Zhanghao Yu, Runze Jiang, Yi Zhou, Youlang Shi, Jiahai Membranes (Basel) Article In recent years, cell membrane drug delivery systems have received increasing attention. However, drug-loaded membrane delivery systems targeting therapy in myocardial ischemia–reperfusion injury (MIRI) have been relatively rarely studied. The purpose of this study was to explore the protective effect of platelet-membrane-encapsulated Carvedilol on MIRI. We extracted platelets from the blood of adult SD rats and prepared platelet membrane vesicles (PMVs). Carvedilol, a nonselective β-blocker, was encapsulated into the PMVs. In order to determine the best encapsulation rate and drug-loading rate, three different concentrations of Carvedilol in low, medium, and high amounts were fused to the PMVs in different volume ratios (drugs/PMVs at 2:1, 1:1, 1:2, and 4:1) for determining the optimum concentration and volume ratio. By comparing other delivery methods, including abdominal injection and intravenous administration, the efficacy of PMVs-encapsulated drug-targeted delivery treatment was observed. The PMVs have the ability to target ischemic-damaged myocardial tissue, and the concentration and volume ratio at the optimum encapsulation rate and the drug-loading rate are 0.5 mg and 1:1. We verified that PMVs@Carvedilol had better therapeutic effects compared to other treatment groups, and immunofluorescence observation showed a significant improvement in the apoptosis indicators and infarction area of myocardial cells. Targeted administration of PMVs@Carvedilol may be a promising treatment for myocardial reperfusion injury, as it significantly improves postinjury cardiac function and increases drug utilization compared to other delivery methods. MDPI 2022-06-10 /pmc/articles/PMC9227294/ /pubmed/35736311 http://dx.doi.org/10.3390/membranes12060605 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhou, Tingting Yang, Xuechao Wang, Tianyi Xu, Mingming Huang, Zhanghao Yu, Runze Jiang, Yi Zhou, Youlang Shi, Jiahai Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury |
title | Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury |
title_full | Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury |
title_fullStr | Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury |
title_full_unstemmed | Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury |
title_short | Platelet-Membrane-Encapsulated Carvedilol with Improved Targeting Ability for Relieving Myocardial Ischemia–Reperfusion Injury |
title_sort | platelet-membrane-encapsulated carvedilol with improved targeting ability for relieving myocardial ischemia–reperfusion injury |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227294/ https://www.ncbi.nlm.nih.gov/pubmed/35736311 http://dx.doi.org/10.3390/membranes12060605 |
work_keys_str_mv | AT zhoutingting plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT yangxuechao plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT wangtianyi plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT xumingming plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT huangzhanghao plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT yurunze plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT jiangyi plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT zhouyoulang plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury AT shijiahai plateletmembraneencapsulatedcarvedilolwithimprovedtargetingabilityforrelievingmyocardialischemiareperfusioninjury |